Proper Name: Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Manufacturer: GlaxoSmithKline Biologicals
- Indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.